On May 8, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the first quarter ending March 31, 2024, along with updates on its business operations. The company reported a strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities. Research and development expenses decreased compared to the previous year, while collaboration expenses increased due to commercial and manufacturing costs. The net loss for the quarter was $116.6 million, a significant increase from the previous year's $53.1 million. CRISPR Therapeutics highlighted the global activation of over 25 treatment centers for its gene-edited cell therapy, CASGEVY™, and the collection of cells from multiple patients. The company also discussed ongoing clinical trials for its next-generation CAR T product candidates, CTX112™ and...Show More

On May 8, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the first quarter ending March 31, 2024, along with updates on its business operations. The company reported a strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities. Research and development expenses decreased compared to the previous year, while collaboration expenses increased due to commercial and manufacturing costs. The net loss for the quarter was $116.6 million, a significant increase from the previous year's $53.1 million. CRISPR Therapeutics highlighted the global activation of over 25 treatment centers for its gene-edited cell therapy, CASGEVY™, and the collection of cells from multiple patients. The company also discussed ongoing clinical trials for its next-generation CAR T product candidates, CTX112™ and CTX131™, and its in vivo gene editing product candidates, CTX310™ and CTX320™. Additionally, CRISPR Therapeutics expanded its pipeline with new pre-clinical programs targeting refractory hypertension and acute hepatic porphyria. The company is advancing a Phase 1 clinical trial for CTX211™ for the treatment of Type 1 Diabetes and continues to explore in vivo editing of hematopoietic stem cells. CRISPR Therapeutics' collaboration with Vertex Pharmaceuticals has led to the approval of CASGEVY in multiple regions for the treatment of sickle cell disease and transfusion-dependent beta thalassemia, with Vertex leading the global development and commercialization.